Angel News
Angel News

Back to Homepage

16th July 2021

Praetura Ventures leads £2.9m investment in Reacta Biotech

A business that is on course to transform the food allergy diagnostics market has secured £2.9m investment in a funding round led by Praetura Ventures with follow-on equity investment from the Development Bank of Wales.  Reacta Biotech (Reacta), which is based in Deeside, North Wales, produces clinical diagnostics kits for food allergy testing. The business improves the efficiency, accuracy and safety of food allergy testing by producing pharmaceutical grade Oral Food Challenges (OFCs), the gold standard test for diagnosing food allergies.


Register / Login now to read full story

In order to read the full story we need you to be registered with us, please click the links below to login or register.

Login / Register

Add a comment:




Enter the characters in the image shown:

Back to Homepage